537 related articles for article (PubMed ID: 30045773)
1. Critical role of FOXO3a in carcinogenesis.
Liu Y; Ao X; Ding W; Ponnusamy M; Wu W; Hao X; Yu W; Wang Y; Li P; Wang J
Mol Cancer; 2018 Jul; 17(1):104. PubMed ID: 30045773
[TBL] [Abstract][Full Text] [Related]
2. Potent FOXO3a Activators from Biologically Active Compound Library for Cancer Therapeutics: An in silico Approach.
Manoharan S; Vedagiri H; Perumal E
Appl Biochem Biotechnol; 2023 Aug; 195(8):4995-5018. PubMed ID: 37017892
[TBL] [Abstract][Full Text] [Related]
3. FOXO3a and Its Regulators in Prostate Cancer.
Habrowska-Górczyńska DE; Kozieł MJ; Kowalska K; Piastowska-Ciesielska AW
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830408
[TBL] [Abstract][Full Text] [Related]
4. miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A.
Qiu X; Dou Y
Biomed Pharmacother; 2017 Apr; 88():430-435. PubMed ID: 28122308
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway.
Liang Z; Wang X; Xu X; Xie B; Ji A; Meng S; Li S; Zhu Y; Wu J; Hu Z; Lin Y; Zheng X; Xie L; Liu B
Mol Cancer; 2017 May; 16(1):96. PubMed ID: 28549468
[TBL] [Abstract][Full Text] [Related]
6. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
7. FOXO3a-interacting proteins' involvement in cancer: a review.
Dong Z; Guo Z; Li H; Han D; Xie W; Cui S; Zhang W; Huang S
Mol Biol Rep; 2024 Jan; 51(1):196. PubMed ID: 38270719
[TBL] [Abstract][Full Text] [Related]
8. SP1 upregulated FoxO3a promotes tumor progression in colorectal cancer.
Yu Y; Peng K; Li H; Zhuang R; Wang Y; Li W; Yu S; Liang L; Xu X; Liu T
Oncol Rep; 2018 May; 39(5):2235-2242. PubMed ID: 29565456
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
10. FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.
Brucker DP; Maurer GD; Harter PN; Rieger J; Steinbach JP
Int J Oncol; 2016 Dec; 49(6):2399-2410. PubMed ID: 27840901
[TBL] [Abstract][Full Text] [Related]
11. Forkhead box protein O3 suppresses uveal melanoma development by increasing the expression of Bcl‑2‑like protein 11 and cyclin‑dependent kinase inhibitor 1B.
Yan F; Liao R; Lin S; Deng X; Little PJ; Zheng W
Mol Med Rep; 2018 Feb; 17(2):3109-3114. PubMed ID: 29257235
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
[TBL] [Abstract][Full Text] [Related]
13. An oncogenic role of miR-592 in tumorigenesis of human colorectal cancer by targeting Forkhead Box O3A (FoxO3A).
Fu Q; Du Y; Yang C; Zhang D; Zhang N; Liu X; Cho WC; Yang Y
Expert Opin Ther Targets; 2016 Jul; 20(7):771-82. PubMed ID: 27167185
[TBL] [Abstract][Full Text] [Related]
14. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
15. Combination of Solamargine and Metformin Strengthens IGFBP1 Gene Expression Through Inactivation of Stat3 and Reciprocal Interaction Between FOXO3a and SP1.
Tang Q; Zheng F; Wu J; Xiao Q; Li L; Hann SS
Cell Physiol Biochem; 2017; 43(6):2310-2326. PubMed ID: 29073599
[TBL] [Abstract][Full Text] [Related]
16. FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
Imada K; Shiota M; Kuroiwa K; Sugimoto M; Abe T; Kohashi K; Yokomizo A; Eto M; Naito S; Oda Y
Prostate; 2017 Feb; 77(2):145-153. PubMed ID: 27699813
[TBL] [Abstract][Full Text] [Related]
17. [FOXO3a signaling pathway in prostate cancer: Progress in studies].
Tao Y; Li LL; Liu SH; Hong M
Zhonghua Nan Ke Xue; 2020 Aug; 26(8):745-750. PubMed ID: 33377739
[TBL] [Abstract][Full Text] [Related]
18. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
19. MiR-96 expression in prostate cancer and its effect on the target gene regulation.
Bao YH; Wang Y; Liu Y; Wang S; Wu B
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4548-4556. PubMed ID: 29131261
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis.
Qian Z; Ren L; Wu D; Yang X; Zhou Z; Nie Q; Jiang G; Xue S; Weng W; Qiu Y; Lin Y
Int J Cancer; 2017 Jun; 140(12):2792-2804. PubMed ID: 28295288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
